pSivida directors take up entitlements under rights issue

Directors of Perth headquartered global bio-nanotech company pSivida Ltd have confirmed that they will be taking up rights to subscribe for pSivida shares under their respective individual eligible entitlements to raise approximately $29 million.

Capital raised from this rights issue will primarily fund the phase III clinical trials of Medidur for the treatment of Diabetic Macular Edema, and phase IIa clinical trials of our lead BioSilicon product, BrachySil which is being developed for the treatment of inoperable pancreatic cancer.

The rights issue is on a non-renounceable 1 for 8 basis to raise approximately $29 million at 60 cents per ordinary share, and has an incorporated top up facility whereby eligible shareholders may apply for additional new ordinary shares in excess of their entitlement at the same price.

The rights issue is not underwritten. The record date for the rights issue was 22 May 2006.


(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

(first time users)
FREE: 8 articles per month + twice daily business email alerts



Rio Tinto$26.71bn
BHP Billiton Iron Ore$24.30bn
North West Shelf Venture$19.62bn
Fortescue Metals Group$12.48bn
Woodside Petroleum$6.09bn
Did you know 20
Did you know 21
Did you know 19
Did you know 18
Did you know 17
Did you know 16
Did you know 15
Did you know 14
Did you know 13
Did you know 12
Did you know 11
Did you know 10
Did you know 9
Did you know 8
Did you know 7
Did you know 6
Did you know 5
Did you know 4
Did you know 3
Did you know 2
Did you know 1

Feedback Form